Subscribe to stay up-to-date with our latest posts

Stock Markets5 minutes ago (Oct 11, 2021 09:26AM ET)

(C) Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid

(Reuters) – The European Union’s drugs regulator said it was evaluating a marketing authorisation for an antibody cocktail developed by Roche and Regeneron (NASDAQ:REGN) for the treatment and prevention of COVID-19 in people above the age of 12.

The European Medicines Agency said on Monday it will assess the risks and benefits of the drug, called Ronapreve, and that it could issue an opinion within two months. The agency has already started a rolling review of the treatment.

EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation